1262215-63-3

Upstream product

• 1262215-61-1 ethyl N-(3-amino-5-fluoro-4-methylphenyl)carbamate 
• 483324-01-2 2-chloro-4-(pyridin-3-yl)pyrimidine 
• 49592-71-4 methyl 4-methyl-3,5-dinitrobenzoate 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 209341-86-6 4-methyl-3,5-dinitro-benzoic acid hydrazide 
• 1262215-55-3 ethyl N-(4-methyl-3,5-dinitro-phenyl)carbamate 
• 1262215-57-5 ethyl N-(3-amino-4-methyl-5-nitro-phenyl)carbamate 
• 1262215-59-7 ethyl N-(3-fluoro-4-methyl-5-nitro-phenyl)carbamate 
• 16533-71-4 3,5-dinitro-p-toluic acid 
• 1692-25-7 3-pyridylboronic acid 

Downstream Products

• 1262215-41-7 N-(3-fluoro-4-methyl-5-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide 
• 1262215-43-9 N-(3-fluoro-4-methyl-5-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethyl-benzamide 

Relevant academic research and scientific papers

FLUORO-SUBSTITUTED COMPOUNDS AS KINASE INHIBITORS AND METHODS OF USE THEREOF

The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and solvates thereof which have kinase inhibitor activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating and preventing a Bcr-Abl, c-Kit or PDGF-R mediated disorder for which one or more kinase inhibitor is indicated, including neoplasia such as chronic myelogenous leukemia or gastrointestinal stromal tumors. The present invention also provides for processes of making the compounds of Formula I, including salts and solvates thereof, and pharmaceutical compositions comprising the same.